Dr Stock Pick HOT News & Alerts!

_______________________________________

FREE Daily Stock Alerts From DrStockPick.com

_______________________________________

Friday October 2, 2009

DrStockPick.com Stock Report!

**************************************************************

Integral Systems, Inc., (Nasdaq: ISYS) today announced its continued partnership with the US Air Force on the Rapid Attack, Identification, Detection and Reporting System Block-10 (RAIDRS RB-10) program. On September 25, the US Air Force Space and Missile Systems Center obligated $27,740,754 to implement the restructure of the program from a 6 fixed and 3 deployable site configuration, to a 5 transportable system construct. The Air Force has approved the system restructure under a contract modification with a ceiling

Dr Stock Pick HOT News & Alerts!

_______________________________________

FREE Daily Stock Alerts From DrStockPick.com

_______________________________________

Wednesday September 23, 2009

DrStockPick.com Stock Report!

**************************************************************

Salon City, Inc. (PINKSHEETS: SALN) announced today that it has signed another advertising contract with Salon Iris Software, which is produced by CMJ Designs Inc. out of Brighton, MI. The fall campaign will appear in BE! Magazine (Beauty Entertainment) and focuses on the software company’s expertise in salon and spa point-of-sale products. Salon Iris is well respected and Beauty Entertainment plans to start getting the word out nationally to Salon City’s upscale salon network.

Abiomed Inc. (NASDAQ: ABMD), a leading provider

At this time, StocksHaven Investments would like to recall and look back at the last few months of equity advice in order to showcase the proven track record. The following is a list of chosen companies which have been nothing short of stellar, giving investors much needed short term and long term gains despite the ongoing hostile recessionary environment.

1. Spongetech Delivery Systems, Inc. (+948% as of April/1/09) [ Article Link ]

2. Mesa Air Group, Inc. (+75% as of April/24/09) [ Article Link ]

3. Hemispherx Biopharma, Inc. (+ 52% as of May/8/09) [ Article Link ]

Much to the delight of Hemispherx BioPharma individual and institutional investors, a reader and follower of StocksHaven Investments has evaluated the Price Per Share potential should Ampligen see FDA approval within the coming weeks.

The following article has been submitted by an investor under the name: Ace Spader

The much anticipated FDA decision on the Hemispherx Biopharma, Inc. drug Ampligen has held a large audience of traders glued to their computers while tirelessly posting rants and raves in various trading forums across the web. Some of the most popular topics have included wild conspiracy theories surrounding the dilutions by the company and the delays by the FDA. Others have postulated about all of the potential uses of Ampligen in the future with a particular emphasis on the pandemic flu. Of all the topics seen on these boards there is one that continues to resurface multiple times

Hemispherx BioPharma Inc.

(Public, AMEX:HEB)

At approximately 3:30pm EST, 5/29/09, StocksHaven Investments began the call conference scheduled with Chairman & CEO of Hemispherx BioPharma Inc., Dr. William Carter. The basis interview was with regards to TheStreet.com’s Adam Feuerstein’s recent article, “Hemispherx’s CFS Drug Is a Long Shot“.  The interview was concluded as of 4:00pm EST, 5/29/09. Many issues and concerns of private individual investors were raised and answered in a both informative and intellectual manner by Dr. Carter.

The exclusive StocksHaven Investments interview:

If you are experiencing technical difficulties, please visit this link. You will be taken to the original source of the mp3 file where your automatic preset media player should

Hemispherx BioPharma Inc.

(Public, AMEX:HEB)

At approximately 4:30pm EST, 5/15/09, StocksHaven Investments began the call conference scheduled with Chairman & CEO of Hemispherx BioPharma Inc., Dr. William Carter. The interview process was a tremendous success and was concluded as of 5:00pm EST, 5/15/09. Many issues and concerns of private individual investors were raised and answered in a both informative and intellectual manner by Dr. Carter.

The exclusive StocksHaven Investments interview: In addition, StocksHaven Investments would like to thank all of the contributors who have helped facilitate and assist with this conference.

Due to the explosive demand for BioPharma companies pending Food and Drug Approval on new and innovative drugs, I will begin focusing on companies which are a few weeks away from their reviews. Taking notice of the recent 3000%, and 1000% over night gains respectively of TTNP and VNDA, the risk versus rewards leans well towards the positive end on these choices.

Moreover, for those who are not high on risk tolerance, investing up to the FDA approval date may still be a very smart investment as these companies are poised to rise leading up to the decision.

Risk: You lose up to 40% as seen from DSCO and VION.OB and NFLD if approval is declined.

Now let’s move onto my first choice:

Hemispherx BioPharma, Inc

(Public, AMEX:HEB)

About: Hemispherx Biopharma, Inc.